Using Pharmacoepidemiology to Examine the Interplay of Sulfonylureas and Infection Risk in Patients With Diabetes Mellitus
CPT: Pharmacometrics & Systems Pharmacology · 2025
DOI: 10.1002/psp4.13308 ↗Kurz gefasst
Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, 2025. Verfasst von Yu-Ying Wu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Graduate Institute of Adult Education, National Kaohsiung Normal University, Kaohsiung, Taiwan. Hauptthemen laut MEDLINE: Diabetes Mellitus, Hypoglycemic Agents, Pneumonia, Registries. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Sulfonylureas (SU) are commonly prescribed as oral hypoglycemic agents for the management of diabetes mellitus (DM). We postulated that SU possess antimicrobial properties due to their structural resemblance to the antimicrobial agent sulfamethoxazole. Using data from Taiwan's National Health Insurance Research Database, we enrolled patients diagnosed with DM between 2000 and 2013 and followed them for a three‐year period. Patients who consistently used SU were categorized into the SU cohort, while those who had never used SU formed the non‐sulfonylurea (non‐SU) cohort. The primary study endpoints were diagnoses of pneumonia and urinary tract infections (UTIs). Within the database, we identified a total of 15,458,554 patients with DM, with 754,601 (4.88%) in the SU cohort and 2,244,436 (14.52%) in the non‐SU cohort. After individual matching based on age, gender, index day, and propensity score of comorbidities, we included 663,056 patients in each cohort. The cumulative incidence of pneumonia and UTI was 29,239 (4.41%) and 60,733 (9.16%) in the SU cohort, respectively, and 24,599 (3.71%) and 56,554 (8.53%) in the non‐SU cohort, respectively. Our findings indicated that the use of SU increased the risk of pneumonia (1.26–1.60 times) and UTI (1.13–1.22 times), while also potentially offsetting the protective effects of metformin. This pharmacoepidemiological study represents a concerted effort to assess latent drug properties that may have a significant impact on the clinical management of patients with DM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Graduate Institute of Adult Education, National Kaohsiung Normal University, Kaohsiung, Taiwan.
- School of Medicine, College of Medicine, I-Shou University, Kaohsiung, Taiwan.
- Department of Neurosurgery, E-Da Hospital, Kaohsiung, Taiwan.
- Division of Infectious Diseases, Department of Internal Medicine, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan.
- Department of Microbiology & Immunology, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
- Division of Endocrine and Metabolism, Department of Internal Medicine, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan.
ORCID-Profile: Yu-Ying Wu, I-Fan Lin, Kuan-Hua Chen
Zitieren
APA
Wu, Y. Y., Lin, I. F., Chen, K. H., Wang, H. H., & Huang, C. K. (2025). Using Pharmacoepidemiology to Examine the Interplay of Sulfonylureas and Infection Risk in Patients With Diabetes Mellitus. CPT: Pharmacometrics & Systems Pharmacology. https://doi.org/10.1002/psp4.13308
Vancouver
Wu YY, Lin IF, Chen KH, Wang HH, Huang CK. Using Pharmacoepidemiology to Examine the Interplay of Sulfonylureas and Infection Risk in Patients With Diabetes Mellitus. CPT: Pharmacometrics & Systems Pharmacology. 2025. doi:10.1002/psp4.13308
BibTeX
@article{Wu2025,
author = {Wu, Yu-Ying and Lin, I-Fan and Chen, Kuan-Hua and Wang, Hsi-Hao and Huang, Chun-Kai},
title = {Using Pharmacoepidemiology to Examine the Interplay of Sulfonylureas and Infection Risk in Patients With Diabetes Mellitus},
journal = {CPT: Pharmacometrics & Systems Pharmacology},
year = {2025},
doi = {10.1002/psp4.13308}
}
EUVIMED